FierceBiotechFierceBioResearcherFierceBiotechITFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Expanded indication for GSK's Boostrix approved

  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

GlaxoSmithKline received approval from the FDA to market Boostrix for adults. The vaccine, which is designed to protect against tetanus, diphtheria and pertussis (whooping cough), was previously approved for ages 10-18. GSK now has the green light to use the booster in adults ages 19-64 as well. Boostrix will join a line of GSK vaccines for adults which also include vaccines against hepatitis A and B and the flu. Release

More stories about Vaccine   GlaxoSmithKline   FDA approval   Boostrix  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.